Thymoquinone alleviates liver fibrosis via miR‐30a‐mediated epithelial‐mesenchymal transition

Geng, Wujun; Li, Chunxue; Zhan, Yating; Zhang, Rongrong; Zheng, Jianjian

doi:10.1002/jcp.30097

Cited by 14 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HSC activation can be stimulated by a variety of factors, such as the pro-fibrogenic TGF-β1. Thus, a combination therapy approach that targets TGF-β, its regulating pathways and the associated inflammatory state may represent an option for liver fibrosis treatment ( Ebrahimkhani et al, 2011 ; Bai et al, 2013 ; Feng et al, 2013 ; Geng et al, 2020 ). In addition, other cytokines can stimulate the fibrotic process in the liver ( Tsuda et al, 2013 ; Youssef et al, 2013 ).…”

Section: Organ Fibrosis Emt and Possible Anti-emt Therapeutic Stratementioning

confidence: 99%

The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders

Gregorio

Robuffo

Spalletta³

et al. 2020

Front. Cell Dev. Biol.

107

View full text Add to dashboard Cite

Fibrosis is a chronic and progressive disorder characterized by excessive deposition of extracellular matrix, which leads to scarring and loss of function of the affected organ or tissue. Indeed, the fibrotic process affects a variety of organs and tissues, with specific molecular background. However, two common hallmarks are shared: the crucial role of the transforming growth factor-beta (TGF-β) and the involvement of the inflammation process, that is essential for initiating the fibrotic degeneration. TGF-β in particular but also other cytokines regulate the most common molecular mechanism at the basis of fibrosis, the Epithelial-to-Mesenchymal Transition (EMT). EMT has been extensively studied, but not yet fully explored as a possible therapeutic target for fibrosis. A deeper understanding of the crosstalk between fibrosis and EMT may represent an opportunity for the development of a broadly effective anti-fibrotic therapy. Here we report the evidences of the relationship between EMT and multi-organ fibrosis, and the possible therapeutic approaches that may be developed by exploiting this relationship.

show abstract

Section: Organ Fibrosis Emt and Possible Anti-emt Therapeutic Stratementioning

confidence: 99%

The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders

Gregorio

Robuffo

Spalletta³

et al. 2020

Front. Cell Dev. Biol.

107

View full text Add to dashboard Cite

show abstract

“…Although the role of miR30a in tumors has been well established, its role in AIH warrants further study. Geng et al found that the herbal extract thymoquinone exerted an anti-brotic effect by upregulating miR30a expression, indicating the anti-brotic potential of miR30a in the liver 23 . Here, we aimed to explore the anti-liver in ammation potential of miR30a transfection in AIH, which is considered to be a liver disease relevant to autoimmunity and in ammation.…”

Section: Discussionmentioning

confidence: 99%

MiR30a Inhibits Inflammation by Targeting Klf14 in Autoimmune Hepatitis

Yuan

Pan

et al. 2021

Preprint

View full text Add to dashboard Cite

MiR30a plays diverse roles in inflammatory diseases, including autoimmune hepatitis (AIH). Klf14 is associated with the inflammation in AIH. We investigated whether miR30a exerts its regulatory function via Klf14. Concanavalin A (Con A)-induced AIH mice were infected with a miR30a agomir or antagomir. MiR30a expression was quantified using qRT-PCR. TargetScan and luciferase reporter assays were used to predict the relationship between miR30a and Klf14. Liver inflammation was evaluated by measuring serum alanine transaminase (ALT) and aspartate aminotransferase (AST) levels, performing histology, and measuring mRNA expressions of inflammatory cytokines and Klf14 by qRT-PCR, protein of Klf14 by western blotting, and Tregs by FACS. MiR30a was downregulated in the hepatocytes (HCs) of AIH mice, which was negatively associated with the liver inflammation. MiR30a overexpression alleviated the inflammation, whereas downregulation of endogenous miR30a aggravated it. The mRNA and protein level of Klf14 were inversely correlated with the miR30a expression. The luciferase reporter assay validated the relationship between Klf14 and miR30a. Moreover, the frequency of Tregs was consistently correlated with the expression of miR30a. MiR30a may play an essential role in AIH, and its ability to regulate the inflammatory responses may, at least partially, be mediated by targeting Klf14 to modulate Tregs.

show abstract

“…It is well known that activated HSCs play a pivotal role in the development of liver fibrosis, being responsible for the excessive accumulation of ECM proteins in the liver [ 127 ]. Another study found that it contributes to the amelioration of liver fibrosis by interfering with epithelial-mesenchymal transition (EMT) by regulating snail family translational repressor 1 (SNAI1), a zinc finger transcription factor protein involved in EMT [ 125 , 128 ].…”

Section: The Role Of Liver-derived Mirnas In Metabolic Regulation And...mentioning

confidence: 99%

Insight into the Inter-Organ Crosstalk and Prognostic Role of Liver-Derived MicroRNAs in Metabolic Disease Progression

et al. 2023

View full text Add to dashboard Cite

Dysfunctional hepatic metabolism has been linked to numerous diseases, including non-alcoholic fatty liver disease, the most common chronic liver disorder worldwide, which can progress to hepatic fibrosis, and is closely associated with insulin resistance and cardiovascular diseases. In addition, the liver secretes a wide array of metabolites, biomolecules, and microRNAs (miRNAs) and many of these secreted factors exert significant effects on metabolic processes both in the liver and in peripheral tissues. In this review, we summarize the involvement of liver-derived miRNAs in biological processes with an emphasis on delineating the communication between the liver and other tissues associated with metabolic disease progression. Furthermore, the review identifies the primary molecular targets by which miRNAs act. These consolidated findings from numerous studies provide insight into the underlying mechanism of various metabolic disease progression and suggest the possibility of using circulatory miRNAs as prognostic predictors and therapeutic targets for improving clinical intervention strategies.

show abstract

Thymoquinone alleviates liver fibrosis via miR‐30a‐mediated epithelial‐mesenchymal transition

Cited by 14 publications

References 45 publications

The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders

The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders

MiR30a Inhibits Inflammation by Targeting Klf14 in Autoimmune Hepatitis

Insight into the Inter-Organ Crosstalk and Prognostic Role of Liver-Derived MicroRNAs in Metabolic Disease Progression

Contact Info

Product

Resources

About